BRAF and cutaneous melanoma: Oncogenic BRAF mutations are associated with the efficacy of BRAF inhibitors, and vemurafenib (BRAF V600E) has been demonstrated to extend the survival in clinical trials of patients with BRAF‐mutated skin melanoma.10